申请人:Kissei Pharmaceutical Co., Ltd.
公开号:EP2402314A1
公开(公告)日:2012-01-04
The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G; -N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.
本发明提供了可用于预防或治疗与血清尿酸水平异常有关的疾病的化合物,这些化合物具有尿酸活性或类似活性。本发明涉及由以下通式(I)代表的具有黄嘌呤氧化酶抑制活性的(氮杂)吲哚衍生物,可用作预防或治疗与血清尿酸水平异常有关的疾病的制剂、其原药或其盐。在式 (I) 中,T 代表硝基或氰基等,环 J 代表芳基或杂芳基等,Q 代表羧基或 5-四唑基等,Y 代表 H、OH、NH2、卤素、硝基、烷基、烷氧基等,X1、X2 和 X3 独立地代表 CR2 或 N,R1 和 R2 独立地代表卤素、氰基、卤代烷基、A-D-E-G;-N(-D-E-G)2等,式中,A代表单键、O、S等;D和G独立地代表任选取代的亚烷基、环烷基、杂环烷基、芳基、杂芳基等;E代表单键、O、S、COO、SO2等。